Home › Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer
 

Keywords :   


Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

2015-04-29 05:17:09| drugdiscoveryonline Home Page

Pfizer Inc. announced recently that XALKORI (crizotinib) received Breakthrough Therapy designation by the U.S

Tags: cell treatment cancer patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05Faisal Islam: Economy is getting better but people may not notice
10.05Sulfate-Free Foamable Solid Cleanser Patented by Johnson & Johnson
10.05Farm Progress America, May 10, 2024
10.05Farm Progress America, May 10, 2024
10.05Comcast releases research on how viewers discover new TV content
10.05Samba TV uses GenAI to provide actionable context for video ads
10.05Roku unveils screensaver ad integrations, ad partnerships and fresh content
10.05Samsung TV Plus partners with MLB, PGA Tour, F1 and ONE Championship
More »